Form 4: Disc Medicine CLO Boosts Stake with Equity Grants

Disc Medicine's Chief Legal Officer, Rahul Khara, acquired 17,000 restricted stock units and 25,500 stock options, increasing his beneficial ownership.

Summary

• Rahul Khara, Chief Legal Officer of Disc Medicine, Inc. (IRON), acquired 17,000 Restricted Stock Units (RSUs) and 25,500 stock options.
• The RSUs represent a contingent right to receive one share of Common Stock each, vesting annually in four 25% installments commencing on February 15, 2027, subject to continued service.
• The stock options have an exercise price of $74.75 and vest in 48 equal monthly installments commencing on March 10, 2026, also subject to continued service.
• Following these transactions, Khara beneficially owns 55,026 shares of Common Stock and 25,500 derivative securities (stock options).
• The reported transactions occurred on February 10, 2026, with the filing dated February 11, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates continued insider alignment and retention through equity grants, which is a standard and healthy practice for executive compensation and suggests confidence in the company's future.

Positives

• Increased alignment of management interests with shareholders through significant equity grants.
• Rahul Khara's beneficial ownership of common stock increased to 55,026 shares, including 233 shares purchased via an Employee Stock Purchase Plan.
• Acquisition of 17,000 Restricted Stock Units (RSUs) at a price of $0, representing future equity ownership.
• Grant of 25,500 stock options with an exercise price of $74.75, providing potential future upside tied to company performance.

Risks

• The value of the acquired RSUs and stock options is directly tied to the future market performance of Disc Medicine, Inc.'s common stock, which is subject to market volatility and company-specific factors.
• Vesting of both the RSUs and stock options is contingent upon Rahul Khara's continued service to the company, posing a risk if his employment ceases before vesting is complete.

Future Outlook

The filing indicates future vesting schedules for both Restricted Stock Units and stock options, contingent on continued service, suggesting a long-term incentive structure for the Chief Legal Officer designed to retain key talent and align their interests with the company's long-term performance.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Legal Officer are a standard practice in the biotechnology and pharmaceutical industries, aiming to align executive compensation with long-term shareholder value creation and retention. This is particularly common in growth-oriented companies like Disc Medicine, Inc., where intellectual property and legal strategy are critical to success.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options, are a common component of executive remuneration across the biotech sector. For instance, similar grants are observed at companies like Moderna (MRNA) for their executives, often tied to multi-year vesting schedules to ensure retention and performance alignment.
• The vesting schedule of 48 equal monthly installments for options and annual 25% installments for RSUs is consistent with typical industry practices designed to incentivize long-term commitment and performance, comparable to structures seen at peer companies in the biopharmaceutical space.

Stakeholder Impact

• Shareholders: Increased alignment of the Chief Legal Officer's interests with shareholder value through equity ownership, potentially fostering long-term strategic decisions.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership and a commitment to retaining key personnel.

Next Steps

• Vesting of 17,000 Restricted Stock Units will commence annually in four 25% installments starting February 15, 2027, subject to continued service.
• Vesting of 25,500 stock options will commence in 48 equal monthly installments starting March 10, 2026, subject to continued service.

Key Dates

Recommendation

While the equity grants to the Chief Legal Officer are a positive sign of insider alignment and retention, a Form 4 filing primarily reports a transactional event and does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance for existing investors, indicating stability in executive incentives, but does not present new fundamental data for a change in investment thesis.

Keywords

Disc Medicine, IRON, Rahul Khara, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, Chief Legal Officer